Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.26 -0.1%	$0.27	$0.20 ▼ $1.48	$67.85M	2.24	1.47 million shs	343,718 shs
IKNA Ikena Oncology	$1.36	$1.21	$0.97 ▼ $1.94	$65.63M	0.45	136,866 shs	5,378 shs
MRKR Marker Therapeutics	$1.49 -0.7%	$1.27	$0.95 ▼ $5.99	$16.85M	1.44	79,141 shs	62,439 shs
VTGN VistaGen Therapeutics	$2.14 -9.9%	$2.31	$1.90 ▼ $4.21	$61.88M	0.7	161,643 shs	276,394 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+0.83%	-7.57%	-7.77%	-42.93%	-72.65%
IKNA Ikena Oncology	-3.55%	-6.21%	+22.52%	+4.62%	-21.84%
MRKR Marker Therapeutics	-1.32%	-11.24%	+35.14%	+15.38%	-68.62%
VTGN VistaGen Therapeutics	+0.85%	-0.42%	-3.25%	-12.50%	-30.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.2938 of 5 stars	4.2	5.0	0.0	2.7	0.8	0.0
IKNA Ikena Oncology	3.5993 of 5 stars	3.3	5.0	0.0	3.6	1.7	1.3
MRKR Marker Therapeutics	4.5586 of 5 stars	3.8	5.0	3.9	3.8	0.8	0.6
VTGN Vistagen Therapeutics	0.9732 of 5 stars	0.0	2.0	0.0	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	493.10% Upside
IKNA Ikena Oncology	2.50	Moderate Buy	$3.00	120.59% Upside
MRKR Marker Therapeutics	3.50	Strong Buy	$13.17	783.67% Upside
VTGN VistaGen Therapeutics	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRKR, VTGN, IKNA, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
4/1/2025	MRKR Marker Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$12.50 ➝ $12.50
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40

(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.38	N/A	N/A	$0.05 per share	5.12
IKNA Ikena Oncology	$9.16M	7.17	N/A	N/A	$2.61 per share	0.52
MRKR Marker Therapeutics	$6.59M	2.56	N/A	N/A	$1.73 per share	0.86
VTGN VistaGen Therapeutics	$1.06M	58.37	N/A	N/A	$4.23 per share	0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
IKNA Ikena Oncology	-$49.23M	-$0.86	N/A	N/A	N/A	N/A	-30.59%	-27.55%	8/14/2025 (Estimated)
MRKR Marker Therapeutics	-$10.73M	-$1.33	N/A	N/A	N/A	-224.46%	-101.87%	-83.02%	8/13/2025 (Estimated)
VTGN VistaGen Therapeutics	-$29.36M	-$1.48	N/A	N/A	N/A	-6,777.08%	-48.12%	-43.80%	8/11/2025 (Estimated)

Latest MRKR, VTGN, IKNA, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.53	-$0.43	+$0.10	-$0.43	$0.18 million	($0.01) million
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	IKNA Ikena Oncology	-$0.21	-$0.18	+$0.03	-$0.18	N/A	N/A
3/31/2025	Q4 2024	MRKR Marker Therapeutics	-$0.28	-$0.42	-$0.14	-$0.42	$5.25 million	$1.22 million
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
IKNA Ikena Oncology	N/A	N/A	N/A	N/A	N/A
MRKR Marker Therapeutics	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
IKNA Ikena Oncology	N/A	15.32	15.32
MRKR Marker Therapeutics	N/A	3.15	3.15
VTGN Vistagen Therapeutics	N/A	9.35	9.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
IKNA Ikena Oncology	75.00%
MRKR Marker Therapeutics	22.39%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.44%
IKNA Ikena Oncology	5.94%
MRKR Marker Therapeutics	14.50%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	232.08 million	Optionable
IKNA Ikena Oncology	70	48.26 million	45.39 million	Not Optionable
MRKR Marker Therapeutics	60	11.31 million	9.67 million	Not Optionable
VTGN VistaGen Therapeutics	40	28.86 million	28.49 million	Optionable

MRKR, VTGN, IKNA, and ADAP Headlines

Recent News About These Companies

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18 at 4:22 AM | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 18 at 12:26 AM | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17 at 7:10 PM | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17 at 5:06 PM | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17 at 4:30 PM | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16 at 10:43 AM | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16 at 8:51 AM | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday

June 3, 2025 | marketbeat.com

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?

May 28, 2025 | marketbeat.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.com

VistaGen at Stifel 2025: Pioneering Acute SAD Treatment

March 20, 2025 | investing.com

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

March 19, 2025 | businesswire.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript

February 15, 2025 | msn.com

VistaGen’s Earnings Call: Progress and Challenges

February 14, 2025 | tipranks.com

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

February 14, 2025 | seekingalpha.com

StemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc Shares

February 14, 2025 | gurufocus.com

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

February 14, 2025 | gurufocus.com

Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript

February 14, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR, VTGN, IKNA, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.26 0.00 (-0.12%)

As of 02:16 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Ikena Oncology NASDAQ:IKNA

$1.36 0.00 (0.00%)

As of 02:13 PM Eastern

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Marker Therapeutics NASDAQ:MRKR

$1.49 -0.01 (-0.67%)

As of 02:18 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

VistaGen Therapeutics NASDAQ:VTGN

$2.14 -0.24 (-9.92%)

As of 02:17 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time